Tourmaline Bio reports positive Phase 2 TRANQUILITY topline: pacibekitug achieves 75-86% hs-CRP reduction vs 15% placebo

Tourmaline Bio, Inc.

• Median time-averaged hs-CRP reduction through Day 90: 75%, 86%, 85% in pacibekitug arms vs 15% placebo (p<0.0001 all arms).
• 87-94% of pacibekitug patients achieved ≥50% hs-CRP reduction vs 19% placebo through Day 90.
• Safety comparable: 54% AEs and 10% SAEs pooled pacibekitug vs 56% and 11% placebo; one COVID-19 death in 25mg quarterly arm.
• First IL-6 inhibitor to show deep hs-CRP reduction with quarterly subcutaneous dosing; supports Phase 3 ASCVD trial design later in 2025.
• Plans to initiate Phase 2 proof-of-concept trial in abdominal aortic aneurysm (AAA) in H2 2025.